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BACKGROUND: Tumour-initiating cells (TICs) or cancer stem cells can exist as a small population in malignant tissues. The signalling
pathways activated in TICs that contribute to tumourigenesis are not fully understood.
METHODS: Several breast cancer cell lines were sorted with CD24 and CD44, known markers for enrichment of breast cancer
TICs. Tumourigenesis was analysed using sorted cells and total RNA was subjected to gene expression profiling and gene set
enrichment analysis (GSEA).
RESULTS: We showed that several breast cancer cell lines have a small population of CD24
 /low/CD44
þ cells in which TICs may
be enriched, and confirmed the properties of TICs in a xenograft model. GSEA revealed that CD24
 /low/CD44
þ cell populations
are enriched for genes involved in transforming growth factor-b, tumour necrosis factor, and interferon response pathways.
Moreover, we found the presence of nuclear factor-kB (NF-kB) activity in CD24
 /low/CD44
þ cells, which was previously
unrecognised. In addition, NF-kB inhibitor dehydroxymethylepoxyquinomicin (DHMEQ) prevented tumourigenesis of CD24
 /low/
CD44
þ cells in vivo.
CONCLUSION: Our findings suggest that signalling pathways identified using GSEA help to identify molecular targets and biomarkers for
TIC-like cells.
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Accumulating evidence suggests that tumour-initiating cells (TICs)
or cancer stem cells—which make up only a small proportion of
heterogeneous tumour cells—possess a greater ability to maintain
tumour formation than other tumour cell types. It has been
proposed that TICs have characteristics in common with normal
stem cells from tumour-prone tissue (Ailles and Weissman, 2007).
For instance, TICs can self-renew and simultaneously produce
differentiated daughter cells that proliferate strongly until they
reach their final differentiated state. Apparent differences also exist
between TICs and normal stem cells. The latter are maintained
under tight homoeostatic regulation and are passively protected in
the surrounding microenvironment or stem cell niche in adult
tissues. However, the former may actively contribute to tumour
formation. Although the concept of TICs greatly influences cancer
biology and evokes a reconsideration of cancer treatment, the
molecular mechanisms involved in the contribution of TICs to
tumourigenesis remain obscure.
In human breast cancers, a population characterised by the
expression of cell-surface markers, CD24
 /low/CD44
high, was
reported to be highly enriched in TICs, compared with populations
of CD24
high/CD44
high cells (Al-Hajj et al, 2003; Mani et al, 2008).
Two gene-expression profiling studies, comparing CD24
 /low/
CD44
þ cell populations with other populations in primary breast
cancer cells or in normal tissue, presented the CD24
 /low/CD44
þ
cell population-derived different signatures that seemed to predict
poorer prognosis (Liu et al, 2007; Shipitsin et al, 2007). One study
showed that transforming growth factor (TGF)-b pathways seem to
be activated in these cells (Shipitsin et al, 2007). It was subsequently
reported that TGF-b induced the epithelial–mesenchymal transi-
tion (EMT) in mammary glands and stem-like cells in both normal
mammary epithelial cells and breast cancer cells (Mani et al, 2008).
Because TGF-b signalling can have positive or negative effects on
tumourigenesis, additional signalling may still be needed to
stimulate tumourigenesis.
Nuclear factor-kB (NF-kB) is a transcription factor complex and
is typically a heterodimer of p50, p52, p65 (RelA), RelB, and c-Rel.
It is usually inactive and bound to IkB, an inhibitory protein, in
the cytoplasm. Upon stimulation with signals such as tumour
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snecrosis factor (TNF) or interferon (INF), IkB is first phosphory-
lated, then ubiquitinated, and finally degraded. Released NF-kB
translocates to the nucleus and binds to the kB sequence, wherein
it promotes the transcription of various genes, including
inflammatory cytokines. Nuclear factor-kB is involved in
inflammation, angiogenesis, inhibition of apoptosis, and tumouri-
genesis (Karin et al, 2002; Huber et al, 2004; Tabruyn and
Griffioen, 2008).
Gene set enrichment analysis (GSEA) is a recently developed
analytical method of gene-expression profiling. The results are
easier to interpret biologically, and the method is more accurate
and robust than individual gene analysis methods, such as fold
change analysis of expression levels (Subramanian et al, 2005).
In this study, we effectively used GSEA to comprehensively
analyse signalling pathways in TICs using breast cancer cell
lines. As a result, we identified multiple signalling pathways
potentially activated in TIC-like cells, including both known and
unknown pathways. We found activity of NF-kB, which was
previously unrecognised, in TIC-like cells. Therefore, it is possible
that the signalling pathways identified using GSEA help to identify
novel candidates of molecular targets that have important roles in
tumourigenesis in human breast cancer TICs.
MATERIALS AND METHODS
Cell culture
Breast cancer cell lines HCC70, HCC1954, MCF7, SK-BR-3, AU-565,
BT-474, T-47D, and MDA-MB-231 were purchased from the
American Type Culture Collection (ATCC, Manassas, VA, USA).
Cells were cultured according to the manufacturer’s instructions.
FACS
Cells were sorted or analysed after staining with CD24-FITC
or CD44-PE antibody (BD Pharmingen, San Jose, CA, USA), and
dead cells were eliminated using propidium iodide (Sigma, Saint
Louis, MO, USA) and FACS VantageSE (BD Biosciences, Bedford,
MA, USA). Data were analysed by FlowJo 7.2.2 Tree Star Inc.
Ashland, OR, USA.
Construction of lentiviral vectors
A third-generation self-inactivating lentiviral transfer vector
plasmid with a gene encoding firefly luciferase or d2Venus (Nagai
et al, 2002) (provided by Dr A Miyawaki, RIKEN, Wako, Japan)
under the control of the elongation factor 1-a (EF1a) promoter was
produced using constructs provided by Dr H Miyoshi (RIKEN,
Tsukuba, Japan) by standard molecular biological techniques
(Miyoshi et al, 1999). These vectors also contained the central
polypurine track and the woodchuck hepatitis virus post-
regulatory element. Viral supernatant was produced by transient
transfection of 293T cells with packaging plasmids (pMDLg/
p.RRE) and HIV rev expression plasmids (pRSV-rev) and was then
pseudotyped with the vesicular stomatitis virus G protein
(pMD.G), as previously described (Bai et al, 2003). High-titre viral
stocks were prepared by ultracentrifugation. The functional titres
of these vectors (HIV-EF1a-Luciferase, HIV-EF1a-d2Venus) were
determined by infection of HeLa cells using a real-time PCR
method (DNA titre; Sastry et al, 2002). All the multiplicity of
infection (MOI) values used in our experiments were calculated
from DNA titres.
Transduction of cells with lentiviral vectors
HCC1954 and MCF7 cells were pelleted and incubated with
viral supernatant at an MOI of 10 in a 1.5-ml Eppendorf
tube. After incubation for 2h at 371Ci n5 %C O 2, cells were
cultured until they were used in in vivo experiments. Because
HIV-EF1a-d2Venus was used for confirmation of transduction
efficiency, HIV-EF1a-Luciferase and HIV-EF1a-d2Venus were
infected simultaneously in separate tubes. After more than three
passages, the cells were used for FACS analysis or in the
xenograft model.
Xenografts
Six-week-old female NOD/SICD mice were anaesthetised with
isoflurane (Abbott Japan, Tokyo, Japan), and then 0.72mg, 60-day-
release b-estradiol (E2) pellets (Innovative Research of America,
Sarasota, FL, USA) were implanted s.c. on the back of the neck
(only in the case of MCF7 implantation). A total of 1 10
2 to
3 10
4 sorted cells were suspended in 1:1 volumes of phosphate-
buffered saline (PBS)( )/Matrigel (BD Biosciences) to produce
100ml of mixture and were then injected into the mammary fat
pads. Dehydroxymethylepoxyquinomicin (DHMEQ) was sus-
pended in 0.5% chloromethyl cellulose and administrated by i.p.
injections of 100ml containing 12mgkg
 1 thrice a week. Control
groups were injected with the same volume of vehicle. All
treatments started on day 2 after tumour cell implantation.
Mice were handled according to the guidelines of the Insti-
tute of Medical Science, University of Tokyo. The experiments
were approved by the committee for animal research at the
institution.
In vivo imaging
Mice under anaesthesia were injected i.p. with 150mgkg
 1 of
luciferin (Promega, Madison, WI, USA) in PBS( ), and images
were recorded by the IVIS Imaging System (Xenogen, Hopkington,
MA, USA) 5min after the injection. The bioluminescence images
were quantified by Living Image software (Xenogen). Observations
by IVIS were continued once a week, immediately after the
injection, up to 4 weeks. In DHMEQ treatment, tumour growth was
monitored by luciferase activity twice a week, for up to 32 days.
Histology analysis
Tumours from xenograft cells were fixed in 10% neutralised
buffered formalin, embedded in paraffin, and then stained with
haematoxylin–eosin (HE).
Microarray analysis
For microarray analysis, 1% of the entire population of the
HCC1954, MCF7, or HCC70 cell line, belonging to
CD24
 CD44
þ, was purified on the basis of the lowest expression
levels of CD24. In addition ten percent of the entire cell population
of each cell line, belonging to CD24
þ/CD44
þ, was purified as the
control population (CD24
þ). There was no significant difference
in tumourigenicity, whether we considered 1 or 10% of the entire
CD24
 /low/CD44
þ population as the TIC population. Microarray
analyses were performed as previously described (Morikawa et al,
2007). Briefly, total RNA was isolated from samples using TRIzol
(Invitrogen, Carlsbad, CA, USA) according to the manufacturer’s
instructions. Six samples were analysed on an Affymetrix high-
density oligonucleotide array, Human Genome U133 Plus 2.0.
Output images were processed by the MAS5 algorithm and globally
scaled to a target intensity of 100. To identify gene-signature-based
differences between CD24
 /low/CD44
þ and CD24
þ/CD44
þ popu-
lations, we performed GSEA (Subramanian et al, 2005). All probe
sets were pre-ranked using the ratio of the geometric mean of each
group’s expression values; thereafter, the ordered probe set list was
used as the GSEA input. The detailed GSEA parameters are as
follows: the number of permutations is 2500, and the permutation
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a small sample size.
Quantification of NF-jB activity
Nuclear extracts were prepared with a Nuclear Extract Kit according
to the manufacturer’s instructions (Active Motif, Carlsbad, CA,
USA). Briefly, CD24
 /low/CD44
þ and CD24
þ/CD44
þ populations
were sorted from the bulk of HCC1954 or MCF7 cells and isolated
from the nuclear extracts. NF-kB p65 activity was measured with a
TransAM NF-kB p65 Transcription Factor Assay kit (Active Motif)
according to the manufacturer’s instructions. Four sets of nuclear
extracts from each population were prepared, and 20mgo fe a c h
extract was used for the p65 NF-kB activity assay.
RESULTS
TIC populations in breast cancer cell lines
To examine whether CD24
 /low/CD44
þ cell populations exist in
various types of breast cancer cell lines, we analysed the expression
of these surface markers in eight breast cancer cell lines by FACS
analysis (Figure 1). We found that each cell line had various
expression levels of CD24 and CD44. HCC1954, MCF7, HCC70, and
MDA-MB-231 cells had relatively high percentages of CD44
þ cell
populations, whereas BT-474, AU-565, SK-BR-3, and T47-D cells
showed low CD44 expression levels. HCC1954, MCF7, and HCC70
cells had a small population of CD24
 /low/CD44
þ cells. This
situation might be similar to that in early-stage breast cancer tissues
in which the TIC population is assumed to be small. To deter-
mine the hierarchical organisation of breast cancer cell lines, we
analysed the tumourigenic potential of the CD24
 /low/CD44
þ and
CD24
þ/CD44
þ cell populations of HCC1954 and MCF7 cell lines.
Tumourigenicity of CD24
 /low/CD44
þ cell populations in
breast cancer cell lines
The in vivo tumourigenicity assay is the gold standard for
identifying TICs (Clarke et al, 2006). Tumourigenicity of TICs
has been examined by using NOD/SCID mouse and measuring
palpable tumours. To improve the quality of the quantitative
results, we used in vivo bioluminescence imaging (IVIS) to
measure tumour growth. We first transduced cells with a lentiviral
vector encoding luciferase or d2Venus (an improved version of
yellow fluorescent protein) cDNA. We measured transduction
efficiency by expression levels of d2Venus using FACS. As
shown in Supplementary Figure 1, high transduction efficiency
was obtained in each cell line: 92.60 and 99.29% for HCC1954
and MCF7 cells, respectively. Next, we transduced a lentiviral
vector expressing luciferase into these cells. Because we used
similar MOI levels for transduction of the lentiviral vectors
expressing luciferase and d2Venus, we expected similar levels
of luciferase expression in each cell line. These were desig-
nated HCC1954-Luc or MCF7-Luc. Cells in CD24
 /low/CD44
þ
populations were considered to be enriched for TICs, and
CD24
þCD44
þ populations were used as controls. We compared
the expression levels of luciferase in both cell populations and
confirmed that there were no significant differences (Supplemen-
tary Figure 2).
Cells were implanted into mammary fat pads of NOD/SCID
mice and tumour growth was measured by quantifying luci-
ferase activity using the IVIS Imaging System. A total of 10000
HCC1954-Luc and MCF7-Luc cells of both populations were
implanted (Figure 2A and C). After 4 weeks, the analysis of
luciferase activity indicated that cells in the CD24
 /low/CD44
þ
populations of HCC1954-Luc and MCF7-Luc generated signifi-
cantly larger tumours than the control populations (Po0.05).
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Figure 1 CD24 and CD44 expression patterns in breast cancer cell lines. Expression patterns of CD24 and CD44 in breast cancer cell lines (HCC1954,
MCF7, HCC70, BT-474, MDA-MB-231, AU-565, SK-BR-3, and T-47D) were analysed by FACS. Anti-CD24 antibody labelled with FITC and anti-CD44
antibody labelled with PE were applied to the analysis. Gates are based on the isotype control corresponding to each cell line.
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2
HCC1954-Luc, we found that tumours were generated only by the
CD24
 /low/CD44
þ population (n¼6) (Figure 2B).
These results indicate that CD24
 /low/CD44
þ populations
in breast cancer cell lines have higher tumourigenicity than
control populations. It is therefore likely that CD24
 /low/CD44
þ
cells in breast cancer cell lines may behave in a manner similar
to TICs.
We also examined the histology of tumours derived from
HCC1954-Luc cells from both populations and from an unsorted
population when 1 10
4 cells of each population were implanted.
HE staining revealed that tumours derived from CD24
 /low/CD44
þ
and unsorted cells showed a similar histology, namely, exclusively
invasive patterns with a variety of morphologies and the stromal
component (Supplementary Figure 3). In contrast, tumours
derived from control cells showed both invasive and differentiated
patterns associated with a smaller stromal component than
CD24
 /low/CD44
þ or unsorted cells.
Gene-expression profiling and GSEA for the identification
of pathways and key effectors in CD24
 /low/CD44
þ cells
To identify expressed genes that were highly enriched in
CD24
 /low/CD44
þ and control cells, we performed DNA micro-
array analysis using HCC1954, MCF7, and HCC70 cell lines that
have small populations of CD24
 /CD44
þ cells. To select cell
populations strictly, we used only CD24
 /CD44
þ cell popu-
lations that accounted for approximately 1% of the entire
population. As control, we used CD24
þ/CD44
þ cell popu-
lations that comprised approximately 10% of the entire popula-
tion. Microarray data were ranked by the expression ratio between
the geometric mean of the CD24
 /low/CD44
þ:CD24
þ/CD44
þ
populations from the three cell lines (Supplementary Table). We
then applied GSEA (Subramanian et al, 2005). Our results showed
that gene sets involving TGF-b pathways and oncogeneic Ras
pathways were upregulated in CD24
 /low /CD44
þ populations
(Figure 3). Moreover, we found that both TNF and IFN response
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Figure 2 Luciferase activities of CD24
 /low/CD44
þ cells in NOD/SCID mice. HCC1954 and MCF7 cells expressing luciferase were sorted by FACS. Ten
per cent of the entire population, belonging to CD24
 /low CD44
þ, was selected as the TIC population (CD24
 ). Ten per cent of the whole population,
belonging to CD24
þ/CD44
þ, was selected as the control (CD24
þ). We transplanted both populations of 1 10
4 HCC1954 cells (A), 1 10
2 HCC1954
cells (B)o f1  10
4 CF7 cells (C) in mammary fat pads of NOD/SCID mice. Luciferase activities were captured by IVIS after 4 weeks (upper panels).
Luciferase activities in implanted sites were quantified (n¼6) (lower graphs). Results are represented as mean±s.d. *Po0.05 (Student’s t-test).
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 /low /CD44
þ
populations.
With regard to individual genes, gene-ontology-based classifica-
tion revealed that genes involved in ‘stemness’, cell proliferation/
maintenance, cell adhesion, cell motility, invasion, angiogenesis,
growth factor/cytokine, immune response/suppression, and
metabolism were highly represented in CD24
 /low /CD44
þ cells
compared with control cell populations. All these genes may
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Figure 3 Gene set enrichment analysis. DNA microarray analyses were performed to compare TIC and control populations of HCC70, HCC1954, and
MCF7. One per cent of the whole population of each cell line, belonging to CD24
 /CD44
þ, purified on the basis of the lowest expression levels of CD24,
was selected as the TIC population. Ten per cent of the whole population, belonging to CD24
þ/CD44
þ, was purified for the control. Microarray data were
ranked using the geometric mean of the expression ratios between the TIC and control populations from the three cell lines, and GSEA was then applied.
GSEA-extracted representative pathways containing genes enriched in the TIC or control populations are shown. In the original GSEA data sets, the
oncogenic Ras pathway is depicted as RAS_ONCOGENIC_SIGNATURE, the TGF-b pathway is depicted as TGFBETA_ EARLY_UP, the IFN response is
depicted as IFN_ANY_UP, and the TNF response pathway is depicted as SANA_TNFA_ENDOTHELIAL_UP.
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found Notch2, a ‘stemness’-related gene, in the TGF-b pathway;
LAMA3, a cell invasion- or adhesion-related gene, in the oncogenic
Ras pathway; and KLF5, EPAS1, and VEGF, angiogenesis-related
genes, in the oncogenic Ras pathway (Figure 3, in red). Conversely,
GSEA revealed that genes highly expressed in control populations
correlated with several cell-cycle-associated gene sets, which have
large numbers of cell proliferation/maintenance-related genes.
One of the important effector molecules common to both TNF
and IFN response pathways is NF-kB. We quantified NF-kB
activities in nuclear extracts of CD24
 /low/CD44
þ and control
populations that were sorted by FACS analysis. We found that the
activity of NF-kB was significantly higher in CD24
 /low/CD44
þ
than in CD24
þ/CD44
þ populations (Figure 4).
The TNF or IFN response pathway is involved in the expression
of many inflammatory cytokines/chemokines. Vascular endothelial
growth factor A, interleukin 8, and chemokine (C-C motif) ligand 5
are among the inflammatory cytokines/chemokines associated
with stroma-like activities (Shono et al, 1996; Moriuchi et al, 1997;
Yoshida et al, 1997; Cho et al, 2007). Among the highly ranked
genes, we also noticed Toll-like receptor 1, another upstream
activator for NF-kB, and stromal cell-derived factor 2-like 1, which
is reported to be upregulated through EMT, an important
biological output of the TGF-b pathway (Massague ´, 2008; Sarrio
et al, 2008; Rakoff-Nahoum and Medzhitov, 2009). We measured
the expression levels of these genes by quantitative RT-PCR and
confirmed that they were expressed at significantly higher levels
in CD24
 /low /CD44
þ populations compared with control cells
(Supplementary Figure 4).
Decreased tumourigenesis in CD24
 /low/CD44
þ
populations after treatment with DHMEQ, a specific
inhibitor for NF-jB
We next examined the role of NF-kB activity in tumourigenesis
using a mouse model. TICs are believed to be important at the
beginning of tumourigenesis or in its recurrence; therefore, we
analysed tumourigenesis at early points from relatively small
numbers of TIC-like cells. We transplanted 10
4 cells of CD24
 /low/
CD44
þ populations into NOD/SCID mice, as shown in Figure 2,
and treated them with DHMEQ, a specific inhibitor for NF-kB
(Umezawa, 2006; Supplementary Results; Supplementary Figures 5
and 6). To analyse the effects occurring during the course of
tumourigenesis, we began inhibitor treatment 2 days after trans-
plantation. We monitored tumour formation by in vivo imaging
and found that the luciferase activities of the tumours derived from
CD24
 /low/CD44
þ cell populations treated with DHMEQ were
significantly decreased compared with that of untreated cell-derived
tumours (Figure 5). This finding suggests that NF-kB functions
as a key effector of tumourigenesis derived from TIC-like cells.
DISCUSSION
In this study, we established a mouse model that may recapitulate
part of the tumourigenic process in TICs, using breast cancer cell
lines. We showed that cells derived from CD24
 /low/CD44
þ
populations resulted in tumours larger than those of CD24
þ/
CD44
þ control populations. Importantly, when as few as 100 cells
were implanted, only CD24
 /low/CD44
þ populations gave rise to
tumours (Figure 2B). This is an important criterion for TICs
(Clarke et al, 2006). Therefore, the CD24
 /low/CD44
þ populations
in cell lines may be enriched with TIC-like cells. Our results
revealed heterogeneity in cell populations divided into TIC-like
cells and other cells. Consistent with our data, it has been recently
reported that other cell lines also have TIC-like cell populations
(Fillmore and Kuperwasser, 2008). Therefore, it is reasonable to
assume that several breast cancer cell lines are heterogeneous and
that they have distinct cell populations: TIC-like cells and other
cells, with both cell types preserving the characteristics of TICs and
other cells in primary cancer tissues to some extent.
Moreover, we labelled cells with a luciferase reporter gene and
established a monitoring system of tumourigenesis in the fat pads
of NOD/SCID mice by sensitive and quantitative in vivo imaging
that can detect as few as 100 cells. Because TICs are thought to be
important in tumourigenesis during transition from the pre-
malignant stage to the malignant stage or during recurrence with a
few tumour cells, this model should be useful for monitoring
tumourigenesis at these stages. Indeed, we were able to validate
candidate targets in TICs using inhibitors for NF-kB in our model
(Figure 5).
Gene-expression profiling combined with GSEA showed that
several signalling pathways and genes are involved in CD24
 /low/
CD44
þ TIC-like cells compared with CD24
þ/CD44
þ control
populations. Gene Ontology Classification revealed that a variety
of genes may represent malignant characteristics of CD24
 /low/
CD44
þ TIC-like cells. There is an overlap with those genes found
in a previous report using cells from CD24
 /low/CD44
þ and
CD24
þ/CD44
þ populations derived from normal breast and
primary breast cancer tissues. Some genes involved in the TGF-b
pathway were enriched in CD24
 /low/CD44
þ populations, con-
sistent with the previous report (Shipitsin et al, 2007). Importantly,
we found genes associated with oncogenic Ras pathways, as well
as with TNF and IFN response pathways, as novel gene sets in
CD24
 /low/CD44
þ populations. It is likely that genes involved in
the oncogenic Ras pathway, the TNF response pathway, and the
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Figure 4 Activity of NF-kB. Quantification of NF-kB activity in CD24
 /
CD44
þ and CD24
þ/CD44
þ populations sorted from HCC1954 (A) and
MCF7 cells (B). The data (mean±s.d.) are representative of three
experiments. *Po0.05.
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Figure 5 Effects on tumourigenesis after treatment with NF-kB inhibitor.
Tumour growth of CD24
 /low/CD44
þ populations of HCC1954 cells
treated with NF-kB inhibitor DHMEQ was measured by luciferase activity
(n¼8). Averages of luciferase activity are indicated by lines. *Po0.05.
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sIFN response pathway are specifically represented in TICs but not
in normal stem cells.
The TGF-b pathway inhibits tumourigenesis when it is the only
pathway activated in cells (Massague ´, 2008). However, in the
malignant state, the TGF-b pathway cooperates with other
pathways to facilitate tumourigenesis. It has been reported that
the oncogenic Ras pathway, inflammatory responses, and activa-
tion of NF-kB are such cooperative pathways (Huber et al, 2004).
These findings suggest that TICs are more malignant than other
cells in cancer. We also cannot rule out the possibility that cell
lines may have additional characteristics that differ from those of
primary cells. For example, cell-cycle-related gene sets found to be
enriched in control cells may somehow reflect in vitro culture
adaptations (Figure 3). The enhanced cell-cycling activity might
allow control cells to grow in vivo after implantation; whereas
control cells derived from primary tissues rarely generate tumours
in vivo (Figure 2).
We showed that activity of NF-kB is higher in TIC-like cells than
in control cells. Moreover, DHMEQ, a highly specific inhibitor for
NF-kB, suppressed tumourigenesis in the TIC-like cells in our
mouse model. This was assessed following treatment that occurred
soon after transplantation. Thus, NF-kB could be a promising
target for treatment of early stages of breast cancer and for the
prevention of recurrence.
Taken together, our findings raise an intriguing possibility: TICs
behave in a manner similar to CAFs and can actively generate and
maintain the cancer stem cell niche, in which NF-kB functions as
the main effector that can induce many secretory proteins,
including cytokines and chemokines. Future studies should focus
on the extensive evaluation of our model by using clinical samples
of breast cancer.
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